Market Overview

Morgan Stanley Shifts To Neutral On Colgate-Palmolive, Cites Emerging Markets Weakness

Share:
Morgan Stanley Shifts To Neutral On Colgate-Palmolive, Cites Emerging Markets Weakness
Related CL
Paws Up: The First Pets ETF Is Here
Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More

General skepticism surrounding the household and personal care industry, weakening fundamentals at Colgate-Palmolive Company (NYSE: CL) and valuation have made Morgan Stanley cautious on the stock. 

The Analyst

Dara Mohsenian downgraded Colgate-Palmolive from Overweight to Equal Weight and lowered his price target from $80 to $69.

The Thesis

Weak first-quarter organic sales results led to the downgrade, although the stock was little changed amid low expectations and a profit beat orchestrated by lower-than-expected ad spend, Mohsenian said in a Monday note.

Organic sales growth slowed to 1.4 percent on an average two-year basis in the last two quarters compared to a 4.5-percent average over five years, which casts doubts on long-term growth potential, the analyst said. Morgan Stanley now estimates 3.5-percent organic sales growth in the long term versus Colgate's 3.5-percent guidance.

Notwithstanding a weakening top-line trend, the valuation of the stock has expanded relative to peers, jumping 700-800 basis points since September, Mohsenian said. 

Colgate suggested on the earnings call that developed market trends are improving, the analyst said. Emerging markets, which Mohsenian said are a key driver of Colgate's premium valuation and a strategic potential "halo," are decelerating. 

Brand demand fragmentation, increased competitive intensity and lower pricing with less inflation and forex pressure are the contributors to a "sustained" emerging market slowdown, according to Morgan Stanley. 

The sell-side firm lowered its 2018 and 2019 EPS estimates for Colgate by 11 percent and 2 percent to $3.17 and $3.38, respectively, citing lower top-line assumptions.

The Price Action

Colgate-Palmolive shares have lost about 10.8 percent year-to-date. The stock was down 2.28 percent to $65.07 at the time of publication Monday. 

Related Links:

With Obstacles To Growth In Sight, Argus Downgrades Clorox

Argus Cites Disappointing Organic Growth In Procter & Gamble Downgrade

Photo by Dwight Burdette/Wikimedia. 

Latest Ratings for CL

DateFirmActionFromTo
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2018ArgusMaintainsBuyBuy
Oct 2018SunTrust Robinson HumphreyDowngradesBuyHold

View More Analyst Ratings for CL
View the Latest Analyst Ratings

Posted-In: Dara MohsenianAnalyst Color Earnings News Downgrades Price Target Top Stories Analyst Ratings Best of Benzinga

 

Related Articles (CL)

View Comments and Join the Discussion!

Buckingham Steps To The Sidelines Following Pinnacle Foods' Strong Run Following Activist Stake

Merger Monday Makes A Return